IMPULSIVE AGGRESSION--BIOLOGIC AND TREATMENT CORRELATES

描述（改编自申请人的摘要）：在各种 社会学，心理学，和生物遗传学因素与冲动， 与人类有预谋的攻击相反， 因素似乎是中枢多巴胺能（5-HT） 神经传递 5-羟色胺在冲动攻击性行为中的调节作用 行为被认为是由于其在神经元抑制中的作用， 它约束行为动作，以响应外部（或内部） 令人厌恶的刺激或挑衅。 在该制剂中，5-HT的作用是 限制个人攻击刺激对象和其他 神经元系统（例如，儿茶酚胺）调节的检测，和/或 对厌恶刺激的反应 在这个时候， 关于特定5-HT受体子系统和 儿茶酚胺，如去甲肾上腺素，在介导 这些行为。 在主要研究者的RSDA（II级）申请的更新中， PI建议进行扩大和系统的研究， 5-HT-1a、5-HT-2a/2c和α-2 NE功能指标之间的关系 冲动性攻击和自杀行为的综合指数 人格障碍（PD）患者。 此外，PI计划扩大其 临床药物试验研究的抗侵略性的功效 氟西汀通过进行9个月的持续治疗和复发/缓解 在PD受试者中进行研究。 反侵略领域的新方向 疗效由氟西汀/认知-行为联合评估来表示。 对男性配偶虐待者的治疗试验。 发展，在当前 授予，一个可靠的标准，冲动性攻击障碍将 允许进一步的工作（即，家庭研究，DNA多态性研究， 流行病学调查），以检验以下各项的全方位结构效度： 冲动性攻击行为作为一个临床实体。 实施的技能 这些和其他研究将在未来五年内获得，如果这 RSDA奖。

DESCRIPTION (Adapted from applicant's abstract): Among the various sociologic, psychologic, and biogenetic factors associated with impulsive, as opposed to premeditated, human aggression, the most consistent biological factor appears to be a reduction in central serotonergic (5-HT) neurotransmission. 5-HT's role in the regulation of impulsive aggressive behavior is thought to arise from its role in neuronal inhibition, through which it constrains behavioral action in response to an outward (or inward) aversive stimulus or provocation. In this formulation, 5-HT acts to restrain the individual from assaulting the object of stimulus and other neuronal systems (e.g., catecholamines) modulate the detection of, and/or the response to, the aversive stimulus. At this time, there is little knowledge regarding this role of specific 5-HT receptor subsystems and of the role of catecholamines, such as norepinephrine, in the mediation of these behaviors. In this renewal of the Principal Investigator's RSDA (Level II) Application, the PI proposes to conduct expanded and systematic studies regarding the relationship between indices of 5-HT-1a, 5-HT-2a/2c, and alpha-2 NE function and comprehensive indices of impulsive aggressive and suicidal behaviors in personality disorder (PD) subjects. In addition, the PI plans to expand his clinical drug trial research regarding the antiaggressive efficacy of Fluoxetine by conducting a nine-month continuation and relapse/remission study in PD subjects. A new direction in this area of antiaggressive efficacy is represented by a combined Fluoxetine/Cognitive-Behavioral treatment trial in male spouse abusers. The development, during the current grant, of reliable criteria for a disorder of Impulsive Aggression will allow further work (i.e., Family Study, DNA Polymorphism Study, Epidemiologic Survey) to test the full spectrum of construct validity for impulsive aggressive behavior as a clinical entity. The skills to implement these and other studies will be acquired during the next five years if this RSDA award.